TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - NYSE:TAK - US8740602052 - ADR
13.44 USD
+0.21 (+1.59%)
13.2002 USD
-0.24 (-1.78%)
Taking everything into account, TAK scores 5 out of 10 in our fundamental rating. TAK was compared to 192 industry peers in the Pharmaceuticals industry. TAK has an excellent profitability rating, but there are concerns on its financial health. TAK has a correct valuation and a medium growth rate. TAK also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
TAK had positive earnings in the past year.
TAK had a positive operating cash flow in the past year.
Each year in the past 5 years TAK has been profitable.
TAK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of TAK (0.98%) is better than 80.73% of its industry peers.
The Return On Equity of TAK (1.99%) is better than 82.81% of its industry peers.
The Return On Invested Capital of TAK (2.18%) is better than 80.21% of its industry peers.
TAK had an Average Return On Invested Capital over the past 3 years of 2.62%. This is significantly below the industry average of 15.40%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.98% | ||
| ROE | 1.99% | ||
| ROIC | 2.18% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
Looking at the Profit Margin, with a value of 3.06%, TAK belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
In the last couple of years the Profit Margin of TAK has grown nicely.
With an excellent Operating Margin value of 9.34%, TAK belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
TAK's Operating Margin has improved in the last couple of years.
TAK's Gross Margin of 64.78% is fine compared to the rest of the industry. TAK outperforms 73.44% of its industry peers.
In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.34% | ||
| PM (TTM) | 3.06% | ||
| GM | 64.78% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
TAK has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
TAK has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TAK has more shares outstanding
Compared to 1 year ago, TAK has an improved debt to assets ratio.
2.2 Solvency
TAK has an Altman-Z score of 1.11. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.11, TAK perfoms like the industry average, outperforming 58.33% of the companies in the same industry.
TAK has a debt to FCF ratio of 5.51. This is a neutral value as TAK would need 5.51 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 5.51, TAK belongs to the best of the industry, outperforming 81.77% of the companies in the same industry.
A Debt/Equity ratio of 0.60 indicates that TAK is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.60, TAK is doing worse than 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 5.51 | ||
| Altman-Z | 1.11 |
ROIC/WACC1.37
WACC1.59%
2.3 Liquidity
TAK has a Current Ratio of 1.16. This is a normal value and indicates that TAK is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.16, TAK is doing worse than 79.17% of the companies in the same industry.
TAK has a Quick Ratio of 1.16. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
TAK has a Quick ratio of 0.59. This is amonst the worse of the industry: TAK underperforms 88.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.16 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
The earnings per share for TAK have decreased strongly by -88.38% in the last year.
The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
Looking at the last year, TAK shows a small growth in Revenue. The Revenue has grown by 7.45% in the last year.
Measured over the past years, TAK shows a small growth in Revenue. The Revenue has been growing by 6.84% on average per year.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)7.45%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
The Earnings Per Share is expected to grow by 51.50% on average over the next years. This is a very strong growth
TAK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.19% yearly.
EPS Next Y112.39%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
EPS Next 5YN/A
Revenue Next Year-1.23%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 192.00, TAK can be considered very expensive at the moment.
77.08% of the companies in the same industry are more expensive than TAK, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.11, TAK is valued quite expensively.
Based on the Price/Forward Earnings ratio of 19.04, the valuation of TAK can be described as rather expensive.
77.60% of the companies in the same industry are more expensive than TAK, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.55. TAK is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 192 | ||
| Fwd PE | 19.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 89.06% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 92.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8 | ||
| EV/EBITDA | 9.03 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TAK has an outstanding profitability rating, which may justify a higher PE ratio.
TAK's earnings are expected to grow with 51.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.71
PEG (5Y)10
EPS Next 2Y79.28%
EPS Next 3Y51.5%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.82%, TAK is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 6.54, TAK pays a better dividend. On top of this TAK pays more dividend than 97.40% of the companies listed in the same industry.
TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.82% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has paid a dividend for at least 10 years, which is a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
TAK pays out 226.17% of its income as dividend. This is not a sustainable payout ratio.
The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP226.17%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
13.44
+0.21 (+1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.43%
Inst Owner Change-0.97%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap42.45B
Revenue(TTM)4581.55B
Net Income(TTM)136.92B
Analysts73.68
Price Target17.65 (31.32%)
Short Float %0.3%
Short Ratio3.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.82% |
Yearly Dividend0.62
Dividend Growth(5Y)1.18%
DP226.17%
Div Incr Years2
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.9%
Min EPS beat(2)-17.13%
Max EPS beat(2)38.94%
EPS beat(4)2
Avg EPS beat(4)13.93%
Min EPS beat(4)-41.58%
Max EPS beat(4)75.5%
EPS beat(8)4
Avg EPS beat(8)-39.26%
EPS beat(12)7
Avg EPS beat(12)-23.29%
EPS beat(16)7
Avg EPS beat(16)-35.41%
Revenue beat(2)0
Avg Revenue beat(2)-4.43%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-2.1%
Revenue beat(4)1
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)6.35%
Revenue beat(8)5
Avg Revenue beat(8)4.21%
Revenue beat(12)8
Avg Revenue beat(12)4.29%
Revenue beat(16)12
Avg Revenue beat(16)4.22%
PT rev (1m)0%
PT rev (3m)2.73%
EPS NQ rev (1m)-20.41%
EPS NQ rev (3m)-22.79%
EPS NY rev (1m)0%
EPS NY rev (3m)4.03%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 192 | ||
| Fwd PE | 19.04 | ||
| P/S | 1.46 | ||
| P/FCF | 8 | ||
| P/OCF | 5.93 | ||
| P/B | 0.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.03 |
EPS(TTM)0.07
EY0.52%
EPS(NY)0.71
Fwd EY5.25%
FCF(TTM)1.68
FCFY12.5%
OCF(TTM)2.27
OCFY16.85%
SpS9.2
BVpS14.1
TBVpS-3.81
PEG (NY)1.71
PEG (5Y)10
Graham Number4.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.98% | ||
| ROE | 1.99% | ||
| ROCE | 3.54% | ||
| ROIC | 2.18% | ||
| ROICexc | 2.27% | ||
| ROICexgc | 9.59% | ||
| OM | 9.34% | ||
| PM (TTM) | 3.06% | ||
| GM | 64.78% | ||
| FCFM | 18.26% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 5.51 | ||
| Debt/EBITDA | 3.54 | ||
| Cap/Depr | 37.97% | ||
| Cap/Sales | 6.36% | ||
| Interest Coverage | 3.67 | ||
| Cash Conversion | 94.32% | ||
| Profit Quality | 597.37% | ||
| Current Ratio | 1.16 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | 1.11 |
F-Score7
WACC1.59%
ROIC/WACC1.37
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y112.39%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
EPS Next 5YN/A
Revenue 1Y (TTM)7.45%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.23%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
EBIT growth 1Y1.04%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year445.18%
EBIT Next 3Y77.79%
EBIT Next 5YN/A
FCF growth 1Y352.48%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y11.95%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the ChartMill fundamental rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for TAK stock?
The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 112.39% in the next year.
How sustainable is the dividend of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 7 / 10 and the dividend payout ratio is 226.17%.